The management of ventricular arrhythmias in cardiac amyloidosis lacks robust guideline recommendations, with ICD therapy potentially beneficial primarily in the early stages of AL amyloidosis.
Answers are grounded in this paper and cite their sources.
Evidence insufficient to guide ICD use in cardiac amyloidosis; leaves open primary prevention benefit in early AL amyloidosis with preserved LVEF.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dumont et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: